\n Data tracked by StockTitan Argus<\/a> (15 min delayed). Upgrade to Gold<\/a> for real-time data. \n <\/p>\n
\n NVO had low short positioning in current risk data, providing context without establishing a directional catalyst. ZEUS remains a clinical readout with safety findings and follow-on trial milestones requiring monitoring.\n <\/p>\n
\n MACE hazard ratio
\n 0.99<\/p>\n
ZEUS Phase 3 trial versus placebo<\/p>\n
\n 95% confidence interval
\n 0.88 to 1.11<\/p>\n
MACE hazard ratio<\/p>\n
\n Trial enrollment
\n over 6,300 people<\/p>\n
ZEUS Phase 3 trial<\/p>\n
\n hsCRP threshold
\n \u22652 mg\/L<\/p>\n
Inflammation eligibility criterion<\/p>\n
\n Ziltivekimab dose
\n 15 mg<\/p>\n
Once-monthly treatment versus placebo<\/p>\n
\n Non-cash impairment charge
\n Q3 2026<\/p>\n
Resulting from the ZEUS outcome<\/p>\n
\n Additional trial readouts
\n First half of 2027<\/p>\n
HERMES and ARTEMIS cardiovascular outcomes trials<\/p>\n
Date
\n Event
\n Sentiment
\n 24h Move
\n Catalyst<\/p>\n
Mar 19<\/p>\n
FDA approval<\/a><\/p>\n Positive<\/p>\n -1.0%<\/p>\n FDA approved Wegovy HD after reported weight-loss results and expanded obesity treatment options.<\/p>\n Pattern Detected<\/p>\n The available prior event showed a negative reaction to favorable FDA approval news, indicating divergence from the announcement’s positive fundamentals.<\/p>\n hazard ratio<\/p>\n medical<\/p>\n “hazard ratio, 0.99; 95% confidence interval, 0.88 to 1.11”<\/p>\n A hazard ratio is a way scientists compare the chance of something happening over time between two groups, like patients taking different medicines. If the ratio is high, it means one group is more likely to experience the event sooner or more often, which helps determine how effective a treatment is or how risky a situation might be.<\/p>\n confidence interval<\/p>\n medical<\/p>\n “95% confidence interval, 0.88 to 1.11”<\/p>\n An interval estimate that shows a range of values within which a true number (like a company\u2019s expected earnings, a projected return, or a model input) is likely to lie, together with a stated level of confidence in that range. For investors it turns a single point forecast into a band\u2014like a weather forecast saying 60\u201370\u00b0F instead of just 65\u00b0F\u2014making uncertainty explicit so you can judge risk and size positions more sensibly.<\/p>\n mace<\/p>\n medical<\/p>\n “major adverse cardiovascular events (MACE) risk reduction”<\/p>\n MACE stands for Major Adverse Cardiovascular Events \u2014 a composite medical endpoint that counts serious heart-related outcomes such as heart attack, stroke and cardiovascular death. Investors use MACE as a single safety and efficacy yardstick for drugs or devices aimed at the heart or blood vessels; like a vehicle crash-test score, a lower MACE rate signals fewer serious harms and can strongly influence regulatory approval, market adoption and commercial value.<\/p>\n monoclonal antibody<\/p>\n medical<\/p>\n “Ziltivekimab is an investigational, fully human monoclonal antibody”<\/p>\n A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.<\/p>\n
![\"\"](\"https:\/\/static.stocktitan.net\/img\/icons\/Google_News_icon.svg\"){kind=icon}
<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/1785535230_850_ti.gif\"\/)
![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/1785535231_126_Novo-Nordisk-A-S.png\")